Pharmawire examines the likely impact that the failure of the late-stage trial for Flurizan [1] will have on R&D projects in the Alzheimer's arena. Experts say that the research could now head in a new direction. Article [2]
Links:
[1] http://www.fiercebiotech.com/story/flurizan-flunks-its-phase-iii-alzheimer-s-test/2008-06-30
[2] http://www.ft.com/cms/s/2/60c1ad04-5183-11dd-a97c-000077b07658,dwp_uuid=e8477cc4-c820-11db-b0dc-000b5df10621.html